In 2009 the first European Society of Clinical Microbiology and Infection (ESCMID) treatment guidance document for Clostridium difficile infection (CDI) was published. The guideline has been applied widely in clinical practice. In this document an update and review on the comparative effectiveness of the currently available treatment modalities of CDI is given, thereby providing evidence-based recommendations on this issue. A computerized literature search was carried out to investigate randomized and non-randomized trials investigating the effect of an intervention on the clinical outcome of CDI. The Grades of Recommendation Assessment, Development and Evaluation (GRADE) system was used to grade the strength of our recommendations and the quality of the evidence. The ESCMID and an international team of experts from 11 European countries supported the process. To improve clinical guidance in the treatment of CDI, recommendations are specified for various patient groups, e.g. initial non-severe disease, severe CDI, first recurrence or risk for recurrent disease, multiple recurrences and treatment of CDI when oral administration is not possible. Treatment options that are reviewed include: antibiotics, toxin-binding resins and polymers, immunotherapy, probiotics, and faecal or bacterial intestinal transplantation. Except for very mild CDI that is clearly induced by antibiotic usage antibiotic treatment is advised. The main antibiotics that are recommended are metronidazole, vancomycin and fidaxomicin. Faecal transplantation is strongly recommended for multiple recurrent CDI. In case of perforation of the colon and/or systemic inflammation and deteriorating clinical condition despite antibiotic therapy, total abdominal colectomy or diverting loop ileostomy combined with colonic lavage is recommended.
Introduction
The previous European Society of Clinical Microbiology and Infection (ESCMID) guidance document, which has been applied widely in clinical practice, dates from 2009 [1] . Meanwhile, new treatments for Clostridium difficile infection (CDI) have been developed and limitations of the currently recommended treatment options of CDI are considered. As the current ESCMID treatment guidance document is already implemented in clinical practice, an update of this widely applied guidance document is essential to further improve uniformity of national hospital infection treatment policies for CDI in Europe. In particular, after the recent development of new alternative drugs for the treatment of CDI (e.g. fidaxomicin) in the USA and Europe, there has been an increasing need for an update on the comparative effectiveness of the currently available antibiotic agents in the treatment of CDI, thereby providing evidence-based recommendations on this issue.
The objectives of this document are to:
1. Provide an overview of currently available CDI treatment options 2. Develop an evidence-based update of treatment recommendations
Update Methodology
Studies on CDI treatment were found with a computerized literature search of PUBMED and Google Scholar using the terms 'Clostridium difficile AND (treatment OR trial)'. All randomized and non-randomized trials investigating the effect of an intervention on the clinical outcome (resolution or recurrence of diarrhoea; incidence of complications) of CDI published in any language were included. Studies investigating carriage or other purely microbiological parameters were not considered sufficient evidence for treatment strategies. The resulting literature from 1978 was reviewed and analysed. Furthermore, systematic reviews from the most recent Cochrane analysis [2] and the up-dated guidelines of the Infectious Diseases Society of America, the Australasian Society for Infectious Diseases, the American College of Gastroenterology, and the Health Protection Agency/Public Health England guidance document (http://www.hpa.org.uk) were evaluated [3] [4] [5] . Recommendations were based on a systematic assessment of the quality of evidence. The Grades of Recommendation Assessment, Development and Evaluation (GRADE) system was used to grade the strength of our recommendations and the quality of the evidence [6, 7] . Draft versions of the guideline were written by the executive committee (consisting of: S. Debast, M. Bauer and E. Kuijper) and criticized by the Executive Committee and advisors. After this, consensus was reached, resulting in the final version. The methods to evaluate the quality of evidence and to reach group consensus recommendations were based on the method described by Ullmann et al. [8] .
Definition of the strength of recommendation is given in Table 1 . The quality of the published evidence is defined in Table 2a . Grouping quality of evidence into three levels only may lead to diverse types of published evidence being assigned specifically to a level II. To increase transparency in the evaluation of the evidence an index (Table 2b ) to the level II recommendations was added where appropriate.
The guideline followed the Appraisal of Guidelines Research and Evaluation Collaboration (AGREE) self-assessment tool [9] .
Definitions Diagnosis
The diagnosis of CDI is based on (1) a combination of signs and symptoms, confirmed by microbiological evidence of C. difficile toxin and toxin-producing C. difficile in stools, in the absence of another cause, or (ii) colonoscopic or histopathological findings demonstrating pseudomembranous colitis [1, 3, [10] [11] [12] .
There are many different approaches that can be used in the laboratory diagnosis of CDI; however, the best standard laboratory test for diagnosis has not been established. Diagnostic tests for CDI include: (i) detection of C. difficile products: cell culture cytoxicity assay (CCA), glutamate dehydrogenase (GDH) and Toxins A and/or B, (ii) toxigenic culture of C. difficile, and (iii) nucleic acid amplification tests (NAAT): 16S RNA, toxin genes, GDH genes. Preferably a twoor three-stage algorithm is performed to diagnose CDI, in which a positive first test is confirmed with one or two confirmatory tests or a reference method [3, 4, 12, 13] . Faeces samples could be investigated with an enzyme immunoassay detecting GDH, an enzyme immunoassay detecting toxins A and B, or NAAT detecting Toxin B (TcdB). Samples with a negative test result can be reported as negative. Faeces samples with a positive first test result should be re-tested with a method to detect free faeces toxins, or with a method to detect GDH or toxin genes, dependent on the assay applied as first screening test. If free faeces toxins are absent but C. difficle TcdB gene or GDH are present, CDI cannot be differentiated from asymptomatic colonization. Recently, a large study was presented in which several diagnostic algorithms were evaluated to optimize the laboratory diagnosis of CDI [14] . The investigators concluded that two-stage algorithms improve diagnosis of CDI. Two commonly recommended methods in the laboratory diagnosis of CDI are the use of GDH detection in stools as a means of screening for CDI, confirmed by NAAT such as PCR to detect toxigenic strains of C. difficile [4, 12] . Furthermore, patients with a positive stool toxin had C. difficile disease with an increased risk of mortality compared with patients with only a positive toxigenic culture, thereby implying that stool toxin testing should be included in a testing algorithm to optimize C. difficile diagnostic testing [15] .
Diarrhoea is defined as loose stools, i.e. taking the shape of the receptacle or corresponding to Bristol stool chart types 5-7, plus a stool frequency of three stools in 24 or fewer consecutive hours or more frequently than is normal for the individual (definition World Health Organization, http://www. who.int/topics/diarrhoea) [1, 3, [16] [17] [18] .
Clinical pictures compatible with CDI are summarized in Table 3 . Definition of Clostridium difficile infection. An episode of CDI is defined as: A clinical picture compatible with CDI and microbiological evidence of free toxins and the presence of C. difficile in stool without reasonable evidence of another cause of diarrhoea. or Pseudomembranous colitis as diagnosed during endoscopy, after colectomy or on autopsy [3, 11, 19] .
Treatment response
Definition of treatment response. Treatment response is present when either stool frequency decreases or stool consistency improves and parameters of disease severity (clinical, laboratory, radiological) improve and no new signs of severe disease develop. In all other cases, treatment is considered a failure. Treatment response should be observed daily and evaluated after at least 3 days, assuming that the patient is not worsening on treatment. Treatment with metronidazole, in particular, may result in a clinical response only after 3-5 days [21] [22] [23] .
After clinical response, it may take weeks for stool consistency and frequency to become entirely normal [23, 24] .
Recurrences
Definition of recurrent Clostridium difficile infection. Recurrence is present when CDI re-occurs within 8 weeks after the onset of a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment [4, 11] . It is not feasible to distinguish recurrence due to relapse (renewed symptoms from already present CDI) from recurrence due to reinfection in daily practice [20, [25] [26] [27] [28] .
Severity of disease
Definition of severe Clostridium difficile infection. Severe CDI is defined as an episode of CDI with (one or more specific signs and symptoms of) severe colitis or a complicated course of disease, with significant systemic toxin effects and shock, resulting in need for ICU admission, colectomy or death [1, 4, 29] .
Clostridium difficile infection without signs of severe colitis in patients with greater age (≥65 years), serious comorbidity, Intensive Care Unit (ICU) admission, or immunodeficiency may also be considered at increased risk of severe CDI [30, 31] .
An overview of characteristics in patients with CDI that are assumed to correlate with the severity of colitis is given in Table 4 [32] [33] [34] [35] [36] [37] [38] [39] . We must stress that the prognostic value of these markers is uncertain.
Clinical prediction markers
Evidence. Clinical studies indicate superiority of specific treatment strategies depending on the severity of disease. In addition, alternative treatment options have been developed, that may be more effective in preventing recurrence of disease. Unfortunately some of the novel treatment strategies can be very expensive, and may only be cost-effective for a certain group of patients depending on the stage and severity of disease. This emphasizes the importance for better identification of clinical markers, preferably early in the course of disease, which might predict the benefit from specific treatment regimens to decrease CDI-related complications, mortality or recurrences. Surprisingly little prospective and validated research has been performed on clinical predictors of outcome [40] . Furthermore, for some complications of CDI, such as ICU admission or death, it is difficult to determine to what extent the complication can be attributed to CDI as opposed to the presenting acute illness(es) or comorbidities.
A wide variety of risk factors for severe or recurrent CDI have been suggested in literature, which makes it difficult to set a rigid clinical prediction rule [1, 25, [41] [42] [43] [44] [45] [46] . Recently, a [1, 3, 11, 19, 20] Sign/symptom Definition
Diarrhoea
Loose stools, i.e. taking the shape of the receptacle or corresponding to Bristol stool chart types 5-7, plus a stool frequency of three stools in 24 or fewer consecutive hours or more frequently than is normal for the individual.
Ileus
Signs of severely disturbed bowel function such as vomiting and absence of stool with radiological signs of bowel distension. Toxic megacolon Radiological signs of distension of the colon (>6 cm in transverse width of colon) and signs of a severe systemic inflammatory response.
systematic review was performed to derive and validate clinical rules to predict recurrences, complications and mortality [46] . Most studies were found to have a high risk of bias because of small sample sizes and much heterogeneity in the variables used, except for leucocytosis, serum albumin and age [46] . Bauer et al. used a database of two randomized controlled trials, which contained information for a large patient group (1105 patients) with CDI, to investigate the prognostic value of three markers for severe CDI. They found that both leucocytosis and renal failure are useful predictors of a complicated course of CDI, if measured on the day of diagnosis [45] . A recent meta-analysis of two pivotal randomized controlled trials comparing fidaxomicin and vancomycin revealed previous vancomycin or metronidazole treatment in the 24 h before randomization, low eosinophil count (<0.1 9 10 9 /L) and low albumin level to be independent predictors of persistent diarrhoea or death in the first 12 days [40] . Recently Miller et al. [36] analysed the same two clinical therapeutic trials to derive and validate a categorization system to discriminate among CDI patients and correlate the grouping with treatment response. They concluded that a combination of five clinical and laboratory variables measured at the time of CDI diagnosis, combined into a scoring system, were able to accurately predict treatment response to CDI therapy with fidaxomicin and vancomycin. These variables include: age, treatment with systemic antibiotics, leucocyte count, albumin and temperature (ATLAS).
Strain type has been suggested as an additional cause of excess morbidity, disease severity and higher recurrence rates of CDI. In a Canadian study [47] , PCR ribotype 027 was correlated with more severe disease and fatal outcome among patients at almost all ages. Some studies on the other hand suggested that PCR ribotype 027 strains might only be associated with worse outcome in settings where 027 strains are epidemic, and not in an endemic situation [38, 48] . However, these findings are questioned by others [49] . Recently, a large study by Walker et al. clearly showed that strain types varied in the overall impact on mortality and biomarkers (predominantly those associated with inflammatory pathways) [50] . Besides C. difficile PCR ribotype 027, other strains are also associated with outbreaks and severe C. difficile infection, e.g. PCR ribotype 078 [51] . Despite increased virulence of specific strain types, the value of the PCR ribotype as a prediction marker for disease severity may be limited, as the ribotype involved in an infection is commonly not known upon diagnosis. However, in an epidemic situation the PCR ribotype may be taken into account in deciding on the choice of empirical treatment regimens [21, 39] .
The level of host immune response to C. difficile exposure has been shown to be an important determinant of the severity and duration of clinical manifestations [52] [53] [54] [55] [56] [57] . Anti-toxin antibody levels have been demonstrated to be higher in healthy adult controls compared with healthy children, and levels were found to fall with increasing age. In addition, anti-toxin antibodies increased after resolution of diarrhoea, which coincided with decreased incidence of CDI recurrence [57] . Inability to mount an adequate humoral immune response (e.g. during use of rituximab) may therefore be an important additional prediction marker for severe and/or recurrent CDI [25, [57] [58] [59] [60] [61] [62] . Unfortunately, in most cases this information is not available at presentation/diagnosis; also, as the strength of evidence for immunodeficiency as an independent predictor for severe and/ or recurrent CDI is still limited, we did not include this risk factor as a separate prediction marker.
The results from individual studies, reviews and meta-analyses on prognostic markers for CDI were evaluated to reach a group consensus on a selection of markers that may be useful in clinical practice to distinguish patients with increased risk for severe or life-threatening CDI and recurrences. For detailed recommendations we refer to Tables 5 and 6.
Recommendations. Clostridium difficile infection is judged to be severe when one or more of the clinical markers of severe colitis mentioned in Table 4 is present, and/or when one or more unfavourable prognostic factors (Table 5) is present:
1. Marked leucocytosis (leucocyte count >15 9 10 9 /L) 2. Decreased blood albumin (<30 g/L) 3. Rise in serum creatinine level (≥133 lM or ≥1.5 times the premorbid level)
Clostridium difficile infection without signs of severe colitis in older patients (≥65 years), serious comorbidity, ICU admission, or immunodeficiency may also be regarded as increased risks of developing severe CDI.
Treatment of Clostridium difficile Infection
Once CDI is diagnosed in a patient, immediate implementation of appropriate infection control measures is mandatory to prevent further spread within the hospital. These include early diagnosis of CDI, surveillance, education of staff, appropriate use of isolation precautions, hand hygiene, protective clothing, environmental cleaning and cleaning of medical equipment, good antibiotic stewardship, and specific measures during outbreaks. Measures for the prevention and control of CDI ('bundle approach') have been described in an ESCMID guideline by Vonberg et al. [73] .
Additional treatment measures include [1, 3, 4, 72, 74] :
Discontinuation of unnecessary antimicrobial therapy Adequate replacement of fluid and electrolytes Avoidance of anti-motility medications Reviewing proton pump inhibitor use
In general it is difficult to compare studies on the treatment of CDI because of the use of variable diagnostic criteria, patient selection and subgroup definitions, stringency of searches for potential enteropathogens, severity of CDI, comorbidities, exposures to causative or concomitant antibiotics, and follow up. Moreover, studies have employed different definitions of clinical and/or microbiological cure and recurrence [2, 75] . The variability in definitions and criteria of randomized controlled trials of antibiotic therapy for CDI is illustrated in Table 7 . In 13/17 randomized controlled trials of antibiotic treatment of initial CDI, recurrences and duration of follow up were defined. Follow up varied from 3 to 6 weeks [32, 41, 46] Large cohort study on CDI mortality at 30 days, and review of studies of factors associated with CDI outcome [41] . Systematic review of studies describing the derivation or validation of Clinical Prediction Rules for unfavourable outcomes of CDI [46] : in general methodological biases and weak validities. Marked leucocytosis (leucocyte count > 15 9 10 9 /L) A IIrht [32, 37, 39, 45, 46, 63, 64] Systematic review [46] : in general methodological biases and weak validities. Cohort study: severity score on malignancy, white blood cell count, blood albumin, and creatinine [37] . Retrospective cohort study on risk factors for severe CDI: death <30 days, ICU, colectomy or intestinal perforation [32] . Decreased blood albumin (<30 g/L) A IIr [32, 37, 40, 46, 65] Systematic review [46] : in general methodological biases and weak validities. Rise in serum creatinine level (≥133 lM or ≥1. 5 times the premorbid level)
A IIht [32, 37, 41, 45] Depending on the timing of measurement around CDI diagnosis [45] .
Comorbidity (severe underlying disease and/or immunodeficiency) B IIht [37, 41, 63, 66] Comorbidity: wide variety of risk factors described/investigated, including cancer, cognitive impairment, cardiovascular, respiratory and kidney disease [41] . Chronic pulmonary disease, chronic renal disease and diabetes mellitus [66] . History of malignancy [37] . Previous operative therapy, inflammatory bowel disease and intravenous immunoglobulin treatment [63] .
a SoR: degree of recommendation to use a (clinical) characteristic as a prognostic marker. [42, 43, 46, 67] Meta-analysis: [43] . Systematic review: [46] . Prospective validation study of risk factor: [42] . Continued use of (non-CDI) antibiotics after diagnosis of CDI and/or after CDI treatment A IIrh [42, 43] Meta-analysis: [43] . Prospective validation study of risk factor: [42] . Comorbidity (severe underlying disease) and/or renal failure A IIh [42, 45, 68] Prospective validation study of risk factor: comorbidity conditions rated by Horns' index (scoring system for underlying disease severity) [42] . A history of previous CDI (more than one recurrence) A IIt [26, 40, [69] [70] [71] Data from randomized controlled trials: [26, 70] . Meta-analysis of pivotal randomized controlled trials [40] . Concomitant use of antacid medications (proton pump inhibitors) B IIrh [43, 72] Meta-analysis on recurrent CDI: [43] . Meta-analysis on CDI: [72] . Initial disease severity B IIth [42, 67] Prospective validation study of risk factor [42] . Long-term population based cohort study [67] . after treatment for CDI. In 6/17 randomized controlled trials definitions for severity of disease were given. In most of the studies very severe and/or life-threatening CDI was excluded.
A Cochrane analysis published in 2011 reviewed 15 studies on the antibiotic treatment for CDI in adults [2] . The risk of bias was rated high in 12 of the 15 included studies. The authors concluded that a specific recommendation for the antibiotic treatment of CDI could not be made. Nevertheless, and in spite of the observed limitations, it is apparent that a clear and up-to-date guideline on the treatment of CDI is urgently needed for clinical practice. For this purpose the strength of a recommendation and the quality of evidence are assigned in two separate evaluations in this guideline, hence allowing an assessment of the strength of a recommendation independent of the level of supportive evidence (Tables 1 and 2) .
To improve clinical guidance in the treatment of CDI, treatment recommendations are specified for various patient groups: A. Initial CDI: non-severe disease B. Severe CDI C. First recurrence or (risk of) recurrent CDI D. Multiple recurrent CDI E. Treatment of CDI when oral administration is not possible
The following treatment options are considered:
1. Oral and non-oral antibiotics 2. Toxin-binding resins and polymers 3. Immunotherapy 4. Probiotics 5. Faecal or bacterial intestinal transplantation [90] More than one recurrence <3 months before study excluded Results specified for CDI <90 days before study.
Return of symptoms (toxin-positive diarrhoea) <31 days after onset of treatment, or clinical response after empiric re-treatment Severe CDI defined as severity assessment score ≥2 (points). Based on: age (1), stools/day (1), temperature (1), Alb (1), WBC (1)
Severe and mild CDI included: results specified Unstable vital signs or ICU excluded. [70] More than one CDI <3 months before study excluded. Results specified for patients with/without CDI <3 months before study.
Reappearance of CD toxin-positive diarrhoea <4 weeks and need for retreatment for CDI Mild, moderate and severe CDI: based on bowel movements/day, WBC Mild, moderate and severe disease included: results specified. Lifethreatening or fulminant CDI and toxic megacolon excluded [91] More than one CDI <3 months before study excluded Results specified for patients with CDI <3 months before study. Evidence. The antibiotics commonly used to treat CDI are oral metronidazole or oral vancomycin. Oral metronidazole has been shown to be effective in inducing a clinical response and has the advantage of low cost and is assumed to be associated with reduced vancomycin-resistant enterococci (VRE) selection risk. In a pooled intention-to-treat analysis (treating exclusions, deaths and relapses as treatment failures) of three randomized controlled trials comparing symptomatic cure between metronidazole and vancomycin [77, 84, 88] , no statistically significant differences were found [2, 75] . Symptomatic cure was achieved in 79% of patients who received vancomycin compared with 71% of patients who received metronidazole (three studies; 335 patients; RR 0.91; 95% CI 0.81-1.03, p 0.14) [2] . However, a recently presented pooled analysis of data from two phase three randomized controlled trials on the use of tolevamer, comparing resolution of diarrhoea and abdominal pain (clinical success) for vancomycin versus metronidazole, showed that overall metronidazole was inferior to vancomycin [92] . Vancomycin significantly improved clinical success (81.1% vs 72.7%; OR 1.681; 95% CI 1.114-2.537; p 0.0134). In addition a retrospective analysis of case records of hospitalized patients with CDI showed that the symptomatic response time was significantly (p <0.01) shorter in patients treated with vancomycin (3.0 days, n = 22) compared with those given metronidazole (4.6 days, n = 28) [23] . Oral metronidazole is usually recommended for treatment of non-severe disease, whereas oral vancomycin is generally preferred for treatment of severe infections [1, [3] [4] [5] .
Return of CD
Decreased clinical effectiveness of metronidazole treatment for specific ribotypes causing CDI, e.g. PCR ribotype 027, has been described [93] . Although changes in antibiotic resistance and ribotype prevalence have been reported, in vitro studies indicate that MICs of metronidazole and vancomycin for endemic C. difficile have remained relatively low over the years. Brazier et al. concluded that the MICs of metronidazole and vancomycin were not indicative of clinical failure, but MICs for epidemic ribotypes (027, 106 and 001) were several dilutions higher [94] . Indeed there is increasing evidence of the emergence of reduced susceptibility to metronidazole in some C. difficile strains, with evidence for clonal spread [95] . Notably, MIC methodology is crucial to the detection of reduced susceptibility to metronidazole; E-tests in particular underestimate the MIC [95, 96] . There is also evidence of inferior microbiological efficacy of metroni-dazole in comparison with vancomycin [21, 22] . Although poor gut concentrations of metronidazole alongside reduced susceptibility to metronidazole could explain reduced treatment efficacy, treatment failures have not been associated with decreased susceptibility [95, 97, 98] . A case-control study found no significant differences in clinical outcome for CDI cases from which strains with reduced susceptibility to metronidazole were recovered versus matched (metronidazole-susceptible) controls [99] . Response to metronidazole was generally poor (slow and prone to recurrence) and the frail elderly patients had a 21% 30-day mortality. However, much larger study groups are needed to determine the clinical significance of CD isolates with reduced susceptibility to metronidazole [99] .
Orally administered vancomycin is poorly absorbed from the gastrointestinal tract, and therefore luminal drug levels are high and orders of magnitude are greater than the susceptibility breakpoint concentration for all strains of C. difficile tested so far, thereby resulting in a more rapid suppression of C. difficile to undetectable levels during therapy and faster resolution of diarrhoea [22, 23] . Metronidazole, on the other hand, is well absorbed from the gastrointestinal tract. Mean antibiotic concentrations reported in faeces of patients receiving oral metronidazole range from <0.25 to 9.5 mg/L, and drug concentrations in faeces decrease to undetectable levels as mucosal inflammation improves and diarrhoea resolves [100] . Increased MIC for metronidazole could therefore have implications on clinical cure or recurrences in CDI. Although there are no published reports in which treatment failure has been linked to antimicrobial metronidazole resistance in C. difficile, the pharmacokinetic properties of vancomycin are considered superior to those of metronidazole in severe C. difficile disease [88] .
There is concern that use of vancomycin may be more likely to promote colonization and transmission of VRE by selection pressure. However, both oral metronidazole and oral vancomycin have been associated with the promotion of persistent overgrowth of VRE in stool samples obtained from colonized patients during CDI treatment, thereby increasing the risk of transmission [101] . In a small study of VRE-colonized patients with CDI, who experienced frequent faecal incontinence, skin and environmental VRE contamination was common during and after resolution of diarrhoea. It was concluded that the frequency of VRE contamination of skin or the environment was similar between patients treated with metronidazole (n = 17) and those given vancomycin (n = 17), although the study clearly had only limited power to examine this issue [102] . In a large retrospective analysis, increased vancomycin use during an outbreak of CDI was not associated with an increase in VRE colonization during a follow-up period of 2 years after the [103] . The authors concluded that restriction of vancomycin use during CDI outbreaks because of the fear of increasing VRE colonization might not be warranted. However, the interpretation of the data was complicated by an outbreak of VRE (VanA) cases that was observed after approximately 20 months of increasing preferential use of vancomycin. As the rate of VanA cases subsequently decreased very quickly, the investigators concluded that this temporary increase reflected a localized clonal outbreak unrelated to the CDI therapy at that time [103] .
Although vancomycin and metronidazole are effective in the treatment of CDI, they are both broader-spectrum agents that cause significant disruption of the commensal colonic microbiota. A disruption in the commensal microbiota may predispose to recurrent CDI and intestinal colonization by healthcare-associated pathogens such as VRE and Candida species. Fidaxomicin appears to cause less disruption of the anaerobic colonization microbiota, and has activity against many VRE strains [104] so it is suggested that the risk of colonization with and transmission of VRE associated with fidaxomicin treatment may be lower compared with vancomycin therapy. A recent study concluded that fidaxomicin was indeed less likely than vancomycin to promote acquisition of VRE and Candida species during CDI treatment. However, selection of pre-existing subpopulations of VRE with elevated fidaxomicin MICs was more common during fidaxomicin therapy [105] .
Similar cure rates have been demonstrated for oral vancomycin and oral teicoplanin [82, 84] . For bacteriological cure, oral teicoplanin may even be more effective than vancomycin [2, 82] . Both glycopeptides are active in vitro against C. difficile isolates [106] . Since 2013 teicoplanin does have a licensed indication for CDI and is available for oral administration. Teicoplanin is not available in the USA. For the purpose of this treatment guideline only oral vancomycin is included in the treatment recommendations. Tables 8 and 9 report the evidence for oral treatment of initial CDI from randomized trials and observational studies with comments on methodology.
Although oral metronidazole absorption is very high and potentially can lead to more systemic side-effects, adverse effects of oral metronidazole are commonly mild to moderate in severity. The most common adverse reactions reported involve the gastrointestinal tract [107] . Rarely, particularly in association with long duration therapy, metronidazole has been linked to more severe safety issues, e.g. peripheral and optic neuropathy [108] and interactions with warfarins [109] .
Oral vancomycin has been shown to be poorly absorbed in most patients, usually producing minimal or subtherapeutic serum concentrations. However, bowel inflammation may enhance absorption of oral vancomycin, particularly in those with renal failure, thereby increasing the risk for systemic side-effects [110] . A recently performed safety analysis of fidaxomicin in comparison with oral vancomycin revealed no differences in serious adverse events between these agents [111] . Fidaxomicin is minimally absorbed. While no specific concerns related to hypersensitivity reactions were identified during the drug development, hypersensitivity reactions associated with fidaxomicin use have been reported to the FDA in the post-marketing phase. The fidaxomicin labeling was revised to include information about the possibility of hypersensitivity reactions [112] .
To evaluate the clinical outcomes of the main antimicrobial agents used in the treatment of CDI, we compared dosages, cure rate, recurrence rate, stated time to response and adverse events of treatment with vancomycin, metronidazole and fidaxomicin. Only randomized controlled trials of antibiotic treatment of initial CDI were included. Results are summarized in Table 10 .
Recommendations. In case of non-severe CDI (no signs of severe colitis) in non-epidemic situations and with CDI clearly induced by the use of antibiotics, it may be acceptable to stop the inducing antibiotic and observe the clinical response for 48 h, but patients must be followed very closely for any signs of clinical deterioration and placed on therapy immediately if this occurs. Metronidazole is recommended as oral antibiotic treatment of initial CDI in mild/moderate disease. For detailed recommendations on oral antibiotic treatment of initial non-severe CDI refer to Table 11 .
Alternative treatment regimens treatment for non-severe disease Evidence. Tables 12 and 13 report the evidence from randomized trials and observational studies on the non-antibiotic treatment of initial CDI, with comments on methodology. The majority of these alternative treatment strategies are combined with antibiotic treatment.
Currently there are no randomized controlled trials on the use of human intravenous gammaglobulins (IVIG). Passive immunizations with IVIG have been reported to be successful in small case series, but the grade of evidence and strength of recommendation of IVIG are too weak to allow recommendations on the use of IVIG in CDI [4, 130] . Hypogammaglobulinaemia, e.g. following solid organ transplants, may predispose to CDI. For this subgroup of patients, IVIG may be beneficial, but more studies are needed before this can be recommended definitively [4] .
A recent systematic review on the use of probiotics suggests that probiotics are associated with a reduction in antibiotic-associated diarrhoea [131] . A recent meta-analysis on probiotic prophylaxis for CDI, concluded that moderate-quality evidence suggests a beneficial effect of probiotic prophylaxis in CDI without an increase in clinically important adverse events [132] . However, a Cochrane analysis concluded that there was insufficient evidence to recommend probiotics, in general, as an adjunct to antibiotics in the treatment of C. difficile diarrhoea [133] . Although no cases of rates. The original protocol was stratified in a group with mild and a group with severe disease (based on age, fever, albumin level and leucocyte count), which resulted in a larger difference between cure rates in the group with severe disease and a statistically non-significant difference between cure rates in the group with mild disease. Intention-to-treat analysis with dropouts regarded as failures resulted in a statistically significant difference between overall cure rates (initial cure minus relapse; 57 out of 90 versus 64 out of 82; risk ratio 0.91). Other comparisons were not significant anymore in the intention-to-treat analysis. [89] Fidaxomicin, 50 mg twice daily, 10 [70] . Contrary to that trial, this trial did show fewer recurrences in both polymerase chain reaction ribotype 027 and non-027 patients, although the difference was not significant for the former subgroup.
translocation of microorganisms have been reported in clinical trials with probiotics for antibiotic-associated diarrhoea or CDI, probiotics should be used with caution. Several studies of invasive disease have been reported, resulting from the use of probiotics such as Saccharomyces boulardii in debilitated or immunocompromised patients [134, 135] . Moreover, probiotics were associated with increased mortality, partly due to non-occlusive mesenteric ischaemia, in a randomized controlled trial in acute pancreatitis [136] .
Recommendations. There is insufficient evidence to support administration of probiotics, toxin-binding resins and polymers, or monoclonal antibodies. For detailed recommendations refer to Table 14 .
B: Severe Clostridium difficile Infection
Oral antibiotic therapy
Evidence. In 6/17 randomized controlled trials, severity of disease was defined. Definitions varied among the studies.
Only in 4/6 of these trials were treatment results specified for severity of disease (Table 15 ).
Recommendations. Based on its pharmacokinetic properties vancomycin is considered superior to metronidazole in severe C. difficile disease [22, 88] . The use of high doses of vancomycin (500 mg orally four times daily) was included in the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America treatment guidelines [3] for management of severe complicated CDI as defined by the treating physician. However, there is insufficient evidence to support the use of doses >125 mg four times daily in the absence of ileus [80] . Fidaxomicin was not inferior to vancomycin for initial cure of CDI, but there are no data available on the efficacy of this drug in severe life-threatening disease [70, 91] .
For detailed recommendations on oral antibiotic treatment of severe CDI refer to Table 16 .
Surgery for complicated Clostridium difficile infection
Evidence. Patients with fulminant CDI who fail to respond and who progress to systemic toxicity, peritonitis, or toxic colonic dilatation and bowel perforation require surgical intervention [4] . Mortality rates of emergency surgery in complicated CDI remain high, ranging from 19% to 71% depending on the clinical condition of the patient at the time of surgery [138] . However, recently a systemic review of the existing literature was performed to assess the effect on mortality of colectomy for the treatment of fulminant CDI. The authors concluded that colectomy is associated with a lower mortality than continued medical treatment when this is no longer improving the patient [139] . Several studies suggest that earlier colectomy (time from presentation to surgery) is associated with improved survival [140] . Independent risk factors for mortality in patients who underwent colectomy that have been found among multiple studies include: the development of shock (need for vasopressors), increased serum lactate (≥5 mM), mental status changes, end organ failure, renal failure and the need for preoperative intubation and ventilation [29, 35, 138, 141, 142] . The more negative prognostic signs a patient has, the earlier surgical consultation and operative management should be considered. The established operative management of severe, complicated CDI has been subtotal colectomy with end-ileostomy [140] . However, recently an alternative surgical treatment with creation of a diverting loop ileostomy, followed by colonic lavage, has been shown to reduce morbidity and mortality, while preserving the colon. The surgical approach involves the laparoscopic creation of a diverting loop ileostomy. The colon is then lavaged in an ante-grade fashion through the ileostomy with a high volume A future alternative to colectomy may be diverting loop ileostomy and colonic lavage, combined with antibiotic treatment (intracolonic antegrade vancomycin and intravenous metronidazole). [84] [85] [86] [87] [88] No statistically significant difference in cure rate between metronidazole and vancomycin or teicoplanin. Statistically significant difference in sustained clinical cure between metronidazole and vancomycin in favour of vancomycin in one study [2, 88] (and pooled results of two randomized controlled trials published only in abstract form [92, 123, 124] Evidence. In 3/17 randomized controlled trials of antibiotic treatment of initial CDI, results were specified for CDI before the study (Table 17) .
Recommendations. The incidence of a second recurrence after treatment of a first recurrence with oral metronidazole or vancomycin is similar. Fewer secondary recurrences with oral fidaxomicin as compared with vancomycin after treatment of a first recurrence are reported [70, 91, 144] . However, the evidence on fidaxomicin for this specific subgroup of CDI patients is limited to two phase III studies and based on a retrospective subset analysis of data and a limited number of patients (number of patients in the modified intention-to-treat analysis: fidaxomicin n = 79 and vancomycin n = 80) [144] . There are no prospective randomized controlled trials performed with metronidazole, vancomycin or fidaxomicin in this specific patient group. In addition, fidaxomicin was not associated with fewer recur- Placebo with standard antimicrobial therapy 99 87 25 65 Industry-sponsored and -analysed. Patients must have diarrhoea and receive vancomycin or metronidazole at time of enrolment. Diarrhoea at least two unformed stools on two consecutive days or more than six unformed stools on 1 day. Recurrence = new episode of diarrhoea with new positive stool toxin test after resolution of initial diarrhoea. Analysis for recurrence only performed in those who were cured, received >7 days of antimicrobial therapy and did not receive intravenous immunoglobulin (93 versus 82). Dropout rate 9 versus 13%, mainly due to deaths not related to CDI. Only 30% (n = 30) of patients treated with vancomycin received monoclonal antibodies versus 22% (n = 22) placebo. Follow up 12 weeks. p <0.001 for comparison of relapse rates. Intention-to-treat analysis. Primary endpoint was changed during the study before unblinding. Original endpoint: resolution of illness. Subgroup analysis: similar results, although difference much smaller in inpatients than outpatients. Length of hospitalization did not differ. a Poster presentation. [70] . Therefore, based on the evidence currently available, the Strength of Recommendation for treating a first recurrence of CDI with oral vancomycin or oral fidaxomicin is considered equal (B-I), unless disease has progressed from non-severe to severe.
For detailed recommendations on oral antibiotic treatment of mild/moderate initial CDI with risk for recurrent CDI or a first recurrence refer to Table 18 . Reduced recurrence of CDI: analysis for recurrence only performed in those who were cured, received >7 days of antimicrobial therapy and did not receive intravenous gammaglobulins Passive immunotherapy with immune whey after standard oral antimicrobial therapy C II [129] Observational study: 101 CDI patients (40% recurrent CDI). Results suggest reduction in recurrence rate.
Probiotics
Oral vancomycin or oral metronidazole + Saccharomyces boulardii D I [126, 137] Comparison of relapse rates: in subgroup analysis efficacy in recurrent CDI, but not in initial CDI. Evidence-based review: [137] . Toxin-binding resins and polymers Tolevamer, 3 g three times daily D I [24] Evidence limited to Phase II randomized controlled trial. Non-inferiority study: tolevamer versus vancomycin. Cure rate lower as compared with vancomycin in severe CDI [88] . Intention to treat analysis not reported. Extremely severe CDI excluded a . Differences in symptomatic cure of metronidazole versus vancomycin not statistically significant in a pooled analysis [2] . ICU admission and hypoalbuminaemia (= disease severity) predictors of metronidazole failure [119] .
a Two studies reported in abstract form confirm the superiority of vancomycin over metronidazole for treatment of (severe) CDI [92, 124, 125] . Evidence. Tables 19 and 20 report the evidence from randomized trials and observational studies with comments on methodology.
Recommendations. In non-severe second (or later) recurrences of CDI oral vancomycin or fidaxomicin is recommended. Vancomycin and fidaxomicin are equally effective in resolving CDI symptoms, but fidaxomicin has been shown to be associated with a lower likelihood of CDI recurrence after a first recurrence [104, 144] . However, there are no prospective randomized controlled trials investigating the efficacy of fidaxomicin in patients with multiple recurrences of CDI. Vancomycin is preferably administered using a tapered and/or pulsed regimen.
Recently the first randomized controlled trial on faecal enteric instillation has been published: faecal transplantation following antibiotic treatment with an oral glycopeptide is reported to be highly effective in treating multiple recurrent CDI [145] .
For detailed recommendations on treatment regimens of multiple recurrent CDI refer to Tables 21 and 22. E: Treatment of Clostridium difficile Infection when oral Administration is not possible Evidence Metronidazole remains the only parenteral antibiotic therapy supported by case series [192] . Intravenous metronidazole (500 mg intravenous three times daily) may be added to oral vancomycin, if the patient has ileus or significant abdominal distension [4, 44] . However, there are no randomized controlled trials available to guide this recommendation.
It is still unknown how to best treat patients with ileus due to CDI. There are some anecdotal reports on delivery of vancomycin to the gut by means other than orally, mainly through intracolonic delivery. Questions regarding the efficacy, optimal dosing and duration of treatment with intracolonic vancomycin remain unanswered [193, 194] . Prospective clinical trials with other antibiotics, like tigecycline, have not yet been performed to support general use [122, 195] . [70, 91] . Retrospective subset analysis: fewer secondary recurrences with fidaxomicin (n = 16/79 patients) as compared with vancomycin (n = 26/80 patients) after treatment of a first recurrence [144] . Fidaxomicin was not associated with fewer recurrences in CDI due to PCR ribotype 027 as opposed to non-027 [70] . Metronidazole, 500 mg three times daily for 10 days C I [27, 88] Recurrence rate: metronidazole not inferior to vancomycin for treatment of mild primary CDI [2, 82, 88] or after a first recurrence [27] . Vancomycin significantly more effective in bacteriological cure than metronidazole in recurrent CDI [69] . Vancomycin, 500 mg four times daily for 10 days C III [80] One randomized controlled trial on dose effectiveness in primary CDI: no significant differences in responses of high-dose compared with low-dose regimens vancomycin. However, results not stratified for recurrent CDI [80] . [69, 150] Retrospective case cohort of two placebo/antibiotic trials [69] : [126, 146] . Observational study: [150] . Expert opinion [3] .
Vancomycin, 125 mg four times daily for 10 days, followed by taper regimen: gradually decreasing the dose to 125 mg per day.
B IIt [69, 150] Retrospective case cohort of two placebo/antibiotic trials [69] : [125, 146] . Observational study: [150] . Expert opinion [3] .
Fidaxomicin, 200 mg twice daily for 10 days B IIrt [75, 144] Evidence limited to two Phase III studies [70, 91] . Retrospective subset analysis: fewer recurrences as compared to vancomycin treatment after first recurrence [144] . Systematic review: [75] . Efficacy after multiple recurrences was not investigated [144] . Vancomycin, 500 mg four times daily for 10 days C IIrt [69, 75] Retrospective case cohort of two placebo/antibiotic trials: [126, 146] . Trend for lower recurrence frequency for high-dose vancomycin [69] . Systematic review: [75] . Metronidazole, 500 mg three times daily for 10 days D IIrt [69, 75] Retrospective case cohort of two placebo/antibiotic trials: [126, 146] . Trend for lower recurrence frequency for high-dose vancomycin and low-dose metronidazole [69] . Systematic review: [75] . 
Summary of Definitions
Episode of CDI. A clinical picture compatible with CDI and microbiological evidence of free toxins and the presence of C. difficile in stool, without reasonable evidence of another cause of diarrhoea.
or Pseudomembranous colitis diagnosed during endoscopy, after colectomy or on autopsy.
Clinical pictures compatible with CDI. Diarrhoea: loose stools, i.e. taking the shape of the receptacle or corresponding to Bristol stool chart types 5-7, plus a stool frequency of three stools in 24 or fewer consecutive hours, or more frequently than is normal for the individual.
Ileus: signs of severely disturbed bowel function such as vomiting and absence of stool with radiological signs of bowel distension.
Toxic megacolon: radiological signs of distension of the colon (>6 cm in transverse width of colon) and signs of a severe systemic inflammatory response.
Severe CDI. Severe or life-threatening CDI is defined as an episode of CDI with (one or more specific signs and symptoms of) severe colitis or a complicated course of disease, with significant systemic toxin effects and shock, resulting in need for ICU admission, colectomy or death.
One or more of the following unfavourable prognostic factors can be present without evidence of another cause:
Marked leucocytosis (leucocyte count >15 9 10 9 /L) Decreased blood albumin (<30 g/L) Rise in serum creatinine level (≥133 lM or ≥1.5 times the premorbid level)
Recurrent CDI. Recurrence is present when CDI re-occurs <8 weeks after the onset of a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment.
Treatment response. Treatment response is present when after therapy either stool frequency decreases or stool consistency improves and parameters of disease severity (clinical, laboratory, radiological) improve and no new signs of severe disease develop. Treatment response should be observed daily and evaluated after at least 3 days, assuming that the patient is not worsening on treatment. Treatment with metronidazole, in particular, may result in a clinical response only after 3-5 days. After clinical response, it may take weeks for stool consistency and frequency to become entirely normal. Also many observational studies and meta-analyses. [164, 186, [189] [190] [191] .
Probiotics
Vancomycin or metronidazole + Saccharomyces boulardii D I [126] Comparison of relapse rates: in subgroup analysis efficacy in recurrent CDI, but not in initial CDI. Evidence-based review: [137] . Vancomycin or metronidazole + Lactobacillus spp. D I [147, 148] Evidence-based review: [137] .
Passive immunotherapy with immune whey
Colostral immune whey D I [149] Study interrupted early. Non-severe disease Intravenous metronidazole 500 mg three times daily for 10 days A IIu [192] Retrospective uncontrolled study [192] . Severe disease and/or complicated or refractory CDI Intravenous metronidazole 500 mg three times daily for 10 days + vancomycin retention enema 500 mg in 100 mL normal saline four times daily intracolonic for 10 days
A B
IIru III [192] [193] [194] Retrospective uncontrolled study [192] . Systematic review [193, 194] . Expert opinion [3] . Intravenous metronidazole 500 mg three times daily for 10 days + vancomycin 500 mg in 100 mL normal saline four times daily by oral/nasogastric tube for 10 days
IIru III [192] [193] [194] Retrospective uncontrolled study [192] . Systematic review [193, 194] . Expert opinion [3] . Intravenous tigecycline 50 mg twice daily for 14 days C III [122] Observational study/case report [122] . 
Summary of Treatment Recommendations
Strength of Evidence (SoE: I to III) and Strength of Recommendation (SoR: A to D) are shown in brackets. For grading definitions we refer to Tables 1 and 2. A: Initial Clostridium difficile Infection: non-severe Disease
Non-antibiotic treatment
In non-epidemic situations and with (non-severe) CDI clearly induced by the use of antibiotics, it may be acceptable to stop the inducing antibiotic and observe the clinical response for 48 h, but patients must be followed very closely for any signs of clinical deterioration and placed on therapy immediately if this occurs. (C-II).
Oral antibiotic treatment
Metronidazole orally 500 mg three times daily for 10 days The use of oral metronidazole in severe CDI or life-threatening disease is strongly discouraged (D-I).
Surgical treatment
Total abdominal colectomy with ileostomy should be performed in case of:
Perforation of the colon Systemic inflammation and deteriorating clinical condition not responding to antibiotic therapy; including toxic megacolon, an acute abdomen and severe ileus.
Surgical treatment should preferably be performed before colitis becomes very severe. Serum lactate may, inter alia, serve as a marker for severity (operate before lactate exceeds 5.0 mM).
A future alternative to colectomy may be diverting loop ileostomy and colonic lavage, combined with antibiotic treatment (intracolonic antegrade vancomycin and intravenous metronidazole).
C: First Recurrence or (Risk of) recurrent Clostridium difficile Infection
Oral antibiotic treatment Fidaxomicin orally 200 mg twice daily for 10 days (B-I) Vancomycin orally 125 mg four times daily for 10 days (B-I) Metronidazole orally 500 mg three times daily for 10 days (C-I) Note: Fidaxomicin was not associated with fewer recurrences in CDI due to PCR ribotype 027 as opposed to non-027 ribotypes.
D: Multiple recurrent Clostridium difficile Infection
Oral antibiotic treatment Fidaxomicin orally 200 mg twice daily for 10 days (B-II) Vancomycin orally 125 mg four times daily for 10 days followed by pulse strategy (B-II) or Vancomycin orally 125 mg four times daily for 10 days followed by taper strategy (B-II) Non-antibiotic treatment in combination with oral antibiotic treatment For multiple recurrent CDI unresponsive to repeated antibiotic treatment, faecal transplantation in combination with oral antibiotic treatment is strongly recommended (A-I).
E: Treatment of Clostridium difficile Infection when oral Administration is not possible

Antibiotic treatment
Non-severe CDI: intravenous metronidazole 500 mg three times daily for 10 days (A-II). It can be considered to increase the oral dosage of vancomycin to 500 mg four times daily for 10 days (B-III); 3 There is no evidence that supports the use of fidaxomicin in life-threatening CDI (D-III); Strength of Recommendation (SoR) A = green (Strongly supports a recommendation for use); SoR B = blue (Moderately supports a recommendation for use); SoR C = grey (Marginally supports a recommendation for use); SoR D=red (Recommendation against use). 
